Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 8, 2005, Pages 683-692

  Vos, Theo ^a,c   Corry, Justine ^b   Haby, Michelle M ^c   Carter, Rob ^d   Andrews, Gavin ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Public Health   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antidepressants; CBT; Cost effectiveness; Depression

Indexed keywords

MIANSERIN; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ARTICLE; AUSTRALIA; BEHAVIOR THERAPY; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; FEASIBILITY STUDY; FUNDING; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL HEALTH SERVICE; MONTE CARLO METHOD; PATIENT COMPLIANCE; PSYCHOTHERAPY; TREATMENT DURATION; TREATMENT PLANNING; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; AUSTRALIA; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MENTAL HEALTH SERVICES;

EID: 27844494626     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2005.01652.x     Document Type: Article

References (46)

1. Australian Bureau of Statistics. Mental health and wellbeing: Profile of adults, Australia, 1997. Canberra: Australian Bureau of Statistics, 1998.
2. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: Measuring the loss of health from diseases, injuries and risk factors. Medical Journal of Australia 2000; 172: 592-596.
3. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004; 38: 389-407.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000; 157: 1-45.
5. Vos T, Haby MM, Barendregt JJ, Kruyshaar ME, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Archives of General Psychiatry 2004; 61: 1097-1103.
6. Haby MM, Carter R, Mihalopoulos C et al. Assessing Cost-Effectiveness - Mental Health: Introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004; 38: 569-578.
7. Stouthard MEA, Essink-Bot ML, Bonsel GJ et al. Disability weights for diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University, 1997.
8. Trindade E, Menon D. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part 1. Evaluation of the clinical literature. Ontario: Canadian Coordinating Office for Health Technology Assessment, 1997.
9. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. Journal of Affective Disorders 2000; 58: 19-36.
10. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000; 132: 743-756.
11. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder (Cochrane Review). In: The Cochrane library, Issue 1. Oxford: Update Software, 2000.
12. Geddes J, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 2003; 361: 653-661.
13. Gloaguen V, Cottraux J, Cucherat M, Blackburn I. A meta-analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders 1998; 49: 59-72.
14. Evans MD, Hollon SD, DeRubeis RJ et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Archives of General Psychiatry 1992; 49: 802-808.
15. Shea MT, Elkin I, Imber SD et al. Course of depressive symptoms over follow-up. Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Archives of General Psychiatry 1992; 49: 782-787.
16. Hollon SD, Evans MD, DeRubeis RJ. Cognitive mediation of relapse prevention following treatment for depression: Implications of differential risk. In: Contemporary psycholgical approaches to depression. New York: Guilford, 1990.
17. Fava GA, Grandi S, SZielezny M, Rafanelli C, Canestrari R. Four-year outcome for cognitive behavoiural treatment of residual symptoms in major depression. American Journal of Psychiatry 1996; 153: 945-947.
18. Paykel ES, Scott J, Teasdale JD et al. Prevention of relapse in residual depression by cognitive therapy: A controlled trial. Archives of General Psychiatry 1999; 56: 829-835.
19. Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. British Journal of Psychiatry 1997; 171: 328-334.
20. Barbui C, Hotopf M, Freemantle N et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: Comparison of drug adherence (Cochrane Review). In: The Cochrane library, Issue 1. Oxford: Update Software, 2001.
21. Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Archives of General Psychiatry 2001; 58: 395-401.
22. Lin EH, Von Korff M, Katon W et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Medical Care 1995; 33: 67-74.
23. Katon W, Rutter C, Ludman EJ et al. A randomized trial of relapse prevention of depression in primary care. Archives of General Psychiatry 2001; 58: 241-247.
24. Katon W, Robinson P, Von Korff M et al. A multifaceted intervention to improve treatment of depression in primary care. Archives of General Psychiatry 1996; 53: 924-932.
25. Antonuccio DO, Thomas M, Danton WG. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (prozac) in the treatment of depression. Behavior Therapy 1997; 28: 187-210.
26. Oei TP, Kazmierczak T. Factors associated with dropout in a group cognitive behaviour therapy for mood disorders. Behaviour Research and Therapy 1997; 35: 1025-1030.
27. Sanderson K, Andrews G, Corry J, Lapsley HM. Modelling change in preference values from descriptive health status using the effect size. Quality of Life Research 2004; 13: 1255-1264.
28. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: A meta-analysis. British Journal of Psychiatry 1997; 170: 205-228.
29. Isacsson G, Bergman U, Rich CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. Journal of Affective Disorders 1996; 41: 1-8.
30. Britt H, Miller G, Charles J et al. General practice activity in Australia 1999-00. AIHW Cat. No. GEP 5. Canberra: Australian Institute of Health and Welfare (General Practice Series no. 5), 2000.
31. Heuzenroeder L, Donnelly M, Haby MM et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Australian and New Zealand Journal of Psychiatry 2004; 38: 602-612.
32. Jick SS, Dean AD, Jick H. Antidepressants and suicide. British Medical Journal 1995; 310: 215-218.
33. Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technology Assessment Reports 2001; 5: 23-24.
34. Drummond M, McGuire A. Economic evaluation in health care. Merging theory with practice. Oxford: Oxford University Press, 2001.
35. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications. Journal of Affective Disorders 1998; 48: 25-36.
36. Judd LL, Akiskal HS, Maser JD et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry 1998; 55: 694-700.
37. Ackerson J, Scogin F, McKendree-Smith N, Lyman RD. Cognitive bibliotherapy for mild and moderate adolescent depressive symptomatology. Journal of Consulting and Clinical Psychology 1998; 66: 685-690.
38. Brown RA, Lewinsohn PM. A psychoeducational approach to the treatment of depression: Comparison of group, individual, and minimal contact procedures. Journal of Consulting and Clinical Psychology 1984; 52: 774-783.
39. Jamison C, Scogin F. The outcome of cognitive bibliotherapy with depressed adults. Journal of Consulting and Clinical Psychology 1995; 63: 644-650.
40. Selmi PM, Klein MH, Greist JH, Sorrell SP, Erdman HP. Computer-administered cognitive-behavioral therapy for depression. American Journal of Psychiatry 1990; 147: 51-56.
41. Schmidt MM, Miller WR. Amount of therapist contact and outcome in a multidimensional treatment program. Acta Psychiatrica Scandinavica 1983; 67: 319-332.
42. Scogin F, Hamblin D, Beutler L. Bibliotherapy for depressed older adults: A self-help alternative. Gerontologist 1987; 27: 383-387.
43. Scogin F, Jamison C, Gochneaur K. Comparative efficacy of cognitive and behavioral bibliotherapy for mildly and moderately depressed older adults. Journal of Consulting and Clinical Psychology 1989; 57: 403-407.
44. Scogin F, Jamison C, Davis N. Two-year follow-up of bibliotherapy for depression in older adults. Journal of Consulting and Clinical Psychology 1990; 58: 665-667.
45. Wollersheim JP, Wilson GL. Group treatment of unipolar depression: A comparison of coping, supportive, bibliotherapy, and delayed treatment groups. Professional Psychology: Research and Practice 1991; 22: 496-502.
46. Gater R, Goldberg D. Pathways to psychiatric care in South Manchester. British Journal of Psychiatry 1991; 159: 90-96.